Simsen News & Stories

From more treatment to smarter treatment: how tumour‑informed ctDNA monitoring can reduce harm and free capacity in cancer care

pontus.rehn@simsendiagnostics.com (Pontus Rehn) — Wed, 17 Dec 2025 10:57:23 GMT

Cancer services across the Nordics are under familiar pressure: rising incidence, tighter staffing, constrained imaging capacity, and a growing expectation that care should be both more precise and more humane. Yet follow‑up pathways are still dominated by a pattern that is, by design, late and often blunt: treat, scan on a fixed schedule, then react.

Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial

Simsen — Mon, 17 Nov 2025 14:30:46 GMT

How Pharma Companies Can Leverage Simsen Diagnostic’s Tumour-Informed ctDNA Analysis to Transform Cancer Drug Trials

Simsen — Tue, 11 Nov 2025 11:03:55 GMT

Developing effective cancer treatments is one of the most challenging frontiers in drug development, where precision, timing, and sensitivity can dramatically influence both clinical outcomes and regulatory success. Traditional trial designs rely on imaging or pathological markers that often fail to capture the early biological response to treatment. Simsen Diagnostics’ tumour-informed ctDNA analysis offers a paradigm shift, allowing real-time, ultra-sensitive molecular monitoring of tumour dynamics. For pharmaceutical companies, it represents not just a diagnostic innovation, but a tool for designing smarter, more efficient, and more informative clinical trials.

Simsen Diagnostics to Present at GoCo Investor Day, Autumn 2025

Simsen — Wed, 09 Jul 2025 13:42:26 GMT

Simsen Diagnostics is excited to announce our participation in the upcoming GoCo Investor Day, a leading gathering for innovation, investment, and collaboration in life sciences.

Simsen Diagnostics' hospital laboratory solution

Simsen — Thu, 26 Jun 2025 10:43:00 GMT

We are proud to announce a new partnership with a Swedish hospital, paving the way for transformative advancements in personalised cancer care. This collaboration empowers hospital laboratories to implement efficient tumour-informed circulating tumour DNA (ctDNA) analysis with ease, precision, and minimal disruption to existing operations.

Simsen Diagnostics to Attend Ecosystem Exchange: Life Sciences 2025

Simsen — Mon, 14 Apr 2025 09:14:02 GMT

We are pleased to announce that our CEO, Pontus Rehn, will represent Simsen Diagnostics at the upcoming Ecosystem Exchange: Life Sciences 2025, hosted by the Swedish Chamber of Commerce for the UK. The event will take place on April 23rd, 2025, at Freeths London, located in the heart of London’s life sciences hub.

Simsen will attend the Swiss Nordic Bio 2025

pontus.rehn@simsendiagnostics.com (Pontus Rehn) — Wed, 26 Feb 2025 16:21:49 GMT

Simsen Diagnostics is excited to announce its participation in the upcoming Swiss Nordic Bio 2025 conference, which will take place in Zurich on March 13th, 2025. Swiss Nordic Bio is a premier high-level partnering and investor conference designed to connect groundbreaking healthcare innovations with leading investors and industry professionals.

Simsen announces collaboration with Buzzard Pharmaceuticals

pontus.rehn@simsendiagnostics.com (Pontus Rehn) — Fri, 21 Feb 2025 14:14:17 GMT

Gothenburg, 21 February 2025

Simsen Diagnostics Partners with Buzzard Pharmaceuticals for Isunakinra Colorectal Cancer Trial

Simsen Diagnostics, a leader in ultrasensitive analysis of nucleic acids, is please to announce a collaboration with Buzzard Pharmaceuticals, a Swedish pharmaceutical company, for their Phase IIa, non-randomized, open-label dose expansion trial. The trial will evaluate isunakinra, an IL-1 inhibitor, in combination with pembrolizumab in patients with metastatic or unresectable, locally advanced colorectal cancer.

Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates

Camilla Hietanen — Fri, 25 Oct 2024 07:45:00 GMT

Gothenburg 2024-10-25: Simsen Diagnostics has signed an agreement with Docrates, a private cancer center in Finland. The agreement allows Docrates to use Simsen’s personalized ctDNA analysis for patient monitoring.

Interview with Ola Nilsson, Neogap Therapeutics

Camilla Hietanen — Fri, 27 Sep 2024 08:00:00 GMT

A few weeks ago, we had the opportunity to meet with Ola Nilsson, Head of Neoantigen Production & Development at Neogap Therapeutics, to discuss their ongoing study. This First-In-Human Phase I/II trial aims to evaluate the safety and effectiveness of a novel T-cell immunotherapy in patients with advanced colorectal cancer.